Vivos Therapeutics, Inc. (VVOS) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated August 14, 2024, serves as a current report for Vivos Therapeutics, Inc., a Delaware corporation. The filing announces the release of financial results for the second quarter ended June 30, 2024. The company is designated as an emerging growth company.
Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is incorporated by reference but not included in the provided text.
Material Changes
The filing does not explicitly detail material changes versus the prior comparable period within the main text. Investors must refer to the referenced press release (Exhibit 99.1) for comparative financial analysis.
Guidance, Outlook, and Risks
The filing does not contain specific management commentary, forward-looking guidance, risk factors, or unusual items in the provided text. The document states that the information in the press release is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Key Facts for Investor Verification
- Verify the specific Q2 2024 financial results (revenue, net loss, cash position) in the press release attached as Exhibit 99.1.
- Confirm the company's cash runway and burn rate, as these are critical for a pre-revenue or early-stage biotech firm.
- Review the full text of the press release for any updates on clinical trial progress or regulatory milestones not detailed in this 8-K summary.
- Note that the financial data in the referenced press release is not legally "filed" under Section 18 of the Exchange Act.